These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37189293)

  • 1. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.
    Stretton B; Kovoor J; Bacchi S; Chang S; Ngoi B; Murray T; Bristow TC; Heng J; Gupta A; Ovenden C; Maddern G; Thompson CH; Heilbronn L; Boyd M; Rayner C; Talley NJ; Horowtiz M
    Intern Med J; 2023 Aug; 53(8):1311-1320. PubMed ID: 37189293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.
    Teague M; Martinez A; Walker E; El-Rifai M; Carris NW
    Clin Ther; 2023 Mar; 45(3):248-261. PubMed ID: 36872170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
    Madsbad S; Holst JJ
    Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
    Amaro A; Sugimoto D; Wharton S
    Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh S; Wright EE; Kwan AY; Thompson JC; Syed IA; Korol EE; Waser NA; Yu MB; Juneja R
    Diabetes Obes Metab; 2017 Feb; 19(2):228-238. PubMed ID: 27717130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GREATER COMBINED REDUCTIONS IN HbA
    Rodbard HW; Bellary S; Hramiak I; Seino Y; Silver R; Damgaard LH; Nayak G; Zacho J; Aroda VR
    Endocr Pract; 2019 Jun; 25(6):589-597. PubMed ID: 30865526
    [No Abstract]   [Full Text] [Related]  

  • 18. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
    Alhindi Y; Avery A
    Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.